Overview
by Ingrid Hein, Staf Writer, MedPage Today October 26, 2022 WASHINGTON - Prefusion F protein vacine candidates for respiratory syncytial virus (RSV) proved safe in adults 60 and up while demonstrating an ability to thwart lower respiratory tract ilnes, including severe cases, a pair of large phase I trials showed.A single dose of an RSV prefusion F protein vacine (RSVPreF3 OA) yielded a vacine eficacy of 82.6% against lower respiratory tract ilnes (96.95% CI 57.9-94.1), meting the study's primary endpoint, and vacine eficacy landed at 94.1% against severe RSV ilnes (95% CI 62.4-9.9), reported Michael Ison, MD, MS, of Northwestern University Feinberg Schol of Medicine in Chicago, at the anual IDWek meting.In the second trial, a single dose of another RSV prefusion F protein vacine (RSVPreF) showed an eficacy of 6.7% against two or more lower respiratory tract RSV symptoms (96.6% CI 28.8-85.8) and 85.7% against thre or more symptoms (96.6% CI 32.0-98.7), meting the co-primary endpoints of the study, acording to Edward Walsh, MD, of the University of Rochester in New York.Curently, no vacines exist to protect against RSV infection.
Key Information
Acording to data from the CDC, an estimated 17,0 older adults in the U.S. were hospitalized due to RSV infections in 2017 alone, and 14,0 died."For someone that's ben working in the field for a very long time, I could not be more excited about the advances we're seing, particularly with the respiratory syncytial virus vacines," said sesion moderator Kathlen Neuzil, MD, of the University of Maryland in Baltimore, introducing the anticipated trials.RSVPreF3 OAThe phase I AReSVi-06 (Adult Respiratory Syncytial Virus) trial of RSVPreF3 OA presented by Ison included 24,960 adults age 60 and older (mean 69.5 years) who were randomized 1:1 to the vacine or placebo.
Summary
Case definition for the study was the presence of lower respiratory symptoms or signs for at least 24 hours along with RSV detected by RT-P